Roche's Xofluza scores trial win in flu prevention, providing sales hope as Tamiflu craters

With sales of Roche’s Tamiflu cratering after it went generic three years ago, the company is anxiously monitoring successor flu drug Xofluza’s chances. Now, the drug has scored new preventative data that could nudge sales upward.